Galapagos NV
F:GXE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Galapagos NV
F:GXE
|
BE |
|
G
|
General Electric Co
PAR:GNE
|
US |
|
Metro Mining Ltd
ASX:MMIDA
|
AU |
Galapagos NV
Galapagos NV is a biotechnology company that discovers and develops medicines for serious diseases, especially in areas like inflammation, fibrosis, and cancer. It uses drug discovery research to find new drug candidates, then advances the most promising ones through clinical testing. Its business is built around turning scientific research into prescription medicines that can eventually be sold by Galapagos or by partners. The company makes money mainly through collaboration payments, milestone payments, and royalties from partners, along with any sales of its own medicines if products reach the market. Its customers are not end patients directly but pharmaceutical partners, healthcare providers, and, through those partners, the patients who use the drugs. This makes Galapagos part of the drug development chain rather than a large-scale drug manufacturer. What makes Galapagos different is that it is a research-heavy biotech with a history of working through partnerships, which helps share the cost and risk of drug development. Like many biopharma companies, its value depends on the quality of its science, the strength of its clinical pipeline, and whether partners or regulators support its drug candidates.
Galapagos NV is a biotechnology company that discovers and develops medicines for serious diseases, especially in areas like inflammation, fibrosis, and cancer. It uses drug discovery research to find new drug candidates, then advances the most promising ones through clinical testing. Its business is built around turning scientific research into prescription medicines that can eventually be sold by Galapagos or by partners.
The company makes money mainly through collaboration payments, milestone payments, and royalties from partners, along with any sales of its own medicines if products reach the market. Its customers are not end patients directly but pharmaceutical partners, healthcare providers, and, through those partners, the patients who use the drugs. This makes Galapagos part of the drug development chain rather than a large-scale drug manufacturer.
What makes Galapagos different is that it is a research-heavy biotech with a history of working through partnerships, which helps share the cost and risk of drug development. Like many biopharma companies, its value depends on the quality of its science, the strength of its clinical pipeline, and whether partners or regulators support its drug candidates.
Transformation: Management framed the quarter as a major strategic reset, highlighted by the planned name change to Lakefront Biotherapeutics and the expected new ticker LKFT on May 8.
Ouro deal: Galapagos said the binding agreement tied to Ouro Medicines and Gilead brings in gamgertamig, a BCMA/CD3 T cell engager for autoimmune disease, plus 3 preclinical programs and meaningfully better capital flexibility than under the legacy agreement.
Capital flexibility: The revised Gilead terms unlock $500 million for uses beyond the Ouro investment, and up to $150 million of that may be used for return of capital to shareholders, subject to limitations.
Quarterly results: Q1 revenue fell to EUR 6.5 million from EUR 75 million a year ago, but the company’s loss narrowed sharply and it posted a EUR 14.5 million net profit, helped by lower operating costs and financial income.
Cash outlook: Management ended the quarter with EUR 2,982.2 million in cash and investments and now expects year-end cash of EUR 1.975 billion to EUR 2.05 billion, while saying the company remains “robustly funded.”
Pipeline focus: The company said gamgertamig showed compelling data in over 60 patients across 5 autoimmune indications, with registrational studies possible as early as 2027.
Next steps: Management said it is still evaluating options for 3667 and expects to make a decision in the not-too-distant future, while keeping the hurdle high for any additional business development deal.
